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Objective. Among patients with rheumatoid ar-
thritis (RA), pain may be attributed to peripheral
inflammation or other causes, such as central pain
mechanisms. The aim of this study was to use self-report
measures and physical examination findings to identify
clusters of RA patients who may have different causes of
pain as well as different prognoses and treatment
options.
Methods. Data from 169 RA patients with pain
scores of >0 (on a 10-point numeric rating scale) in the
Brigham and Women’s Hospital Rheumatoid Arthritis
Sequential Study were analyzed. The patients completed
questionnaires on pain, fatigue, and psychosocial fac-
tors. A hierarchical agglomerative clustering procedure
with Ward’s method was used to obtain subgroups.
Multivariate analysis of variance was used to determine
the contribution of each variable in a cluster. General
linear regression models were used to examine differ-
ences in clinical characteristics across subgroups. Dis-
criminant analyses were performed to determine coeffi-
cients for linear combinations of variables that assigned
cluster membership to individual cases.
Results. Three clusters best fit these data. Cluster
1 consisted of 89 individuals with low levels of inflam-
mation, pain, fatigue, and psychosocial distress. Cluster
2 consisted of 57 individuals with minimal inflammation
but high levels of pain, fatigue, and psychosocial dis-
tress. Cluster 3 consisted of 23 individuals with active
inflammatory disease, manifested by high swollen joint
counts, high C-reactive protein levels, and high levels of
pain and fatigue.
Conclusion. Although most patients had low lev-
els of inflammation, pain, and fatigue, 47.3% continued
to report having moderate to high levels of pain and
fatigue. Most of these patients had minimal signs of
inflammation but high levels of fatigue, pain catastro-
phizing, and sleep disturbance, indicative of a chronic
widespread pain syndrome.
Rheumatoid arthritis (RA) is the most common
systemic rheumatic disease, affecting1.5 million adults
in the United States (1). Historically, physicians have
focused on the inflammatory components of the disease
(e.g., synovitis), whereas RA patients have cited pain,
fatigue, sleep problems, and other quality of life out-
comes as their main priorities (2). Both patients and
physicians frequently assume that these symptoms are
correlated with heightened systemic inflammation. How-
ever, many studies indicate that there is significant
discordance between inflammation, pain, and fatigue
among RA patients (3,4).
In a prospective observational cohort of patients
with established RA whose inflammatory disease was in
sustained remission, 12% continued to report experienc-
ing clinically significant pain (pain score 4 on a 10-
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point numeric rating scale) (5). A study that included
2,096 RA patients in a clinic setting and 14,607 RA
patients from a survey-based cohort showed that the
correlations between fatigue and measures of inflamma-
tion were weak (correlation coefficients 0.07–0.11) (6).
Similarly, van Hoogmoed and colleagues found no asso-
ciation between fatigue and either the erythrocyte sedi-
mentation rate or the C-reactive protein (CRP) level
among 228 patients with RA in an outpatient setting in
The Netherlands (7). These observations suggest that
patient-reported outcomes, such as pain, fatigue, and
sleep problems, should not be automatically attributed
to inflammation in an inflammatory disease population
such as RA.
Central, noninflammatory pain conditions, such
as fibromyalgia, tend to be associated with high levels of
pain, fatigue, and sleep problems (8,9). Compared to the
general population (10,11), the prevalence of noninflam-
matory pain conditions is significantly higher in patients
with RA, with 15–25% of RA patients also meeting the
criteria for fibromyalgia, and an additional 7–15% of RA
patients meeting the criteria for chronic widespread pain
(12,13). Thus, although it is not debated that RA is an
inflammatory condition, many patients with RA also
have features (e.g., fatigue, sleep disturbances) that are
characteristic of noninflammatory, centralized pain
conditions.
The objective of this study was to determine
whether subgroups of RA patients could be character-
ized by a latent construct, representing the involvement
of central, noninflammatory pain processes. The latent
construct was defined by grouping individuals based on
the presence or absence of symptoms indicative of
aberrant central nervous system involvement (e.g., fa-
tigue, sleep problems, negative mood, catastrophic attri-
butions, and perception of overall illness burden), using
cluster analysis. Whereas factor analysis aggregates vari-
ables into patterns based on correlations, cluster analysis
categorizes individuals into nonoverlapping subgroups
(14). Cluster analysis is particularly valuable in identify-
ing subgroups of patients who may differ in terms of
their underlying pathogenic mechanisms and clinical
outcomes (15). The identification of clinically distinct
phenotypes within a heterogeneous population of RA
patients would be the first step in understanding the
pathogenic mechanisms underlying each symptom clus-
ter and, ultimately, in identifying potential targets for
treatment. The variables used in this cluster analysis
were markers of central pain processes, similar to those
included in a previous cluster analysis examining the role
of central, noninflammatory pain in osteoarthritis (16).
We hypothesized that we could identify at least 3
subgroups of RA patients based on cluster analyses, with
the first group comprising RA patients with well-
controlled disease, minimal fatigue, and low psychoso-
cial distress, the second group comprising RA patients
with active inflammatory joint pain and moderate levels
of psychosocial distress, and the third group comprising
RA patients with low swollen joint counts and high levels
of pain, fatigue, and other symptoms characteristic of a
chronic, noninflammatory pain syndrome. This hypothe-
sis was based on clinical observations, as well as on
studies in patients with other painful chronic conditions.
In these prior studies, similar subgroups were identified,
consisting of 1) participants predominantly affected by
peripheral pain generators (e.g., joint inflammation
and/or mechanical and structural markers), and 2) par-
ticipants in whom inflammation and/or mechanical fac-
tors appear to have minimal impact compared to the
influence of central, noninflammatory pain processes
(16,17). Additional subgroups may also exist. For exam-
ple, other reports have described a group of patients
with high levels of depression but low levels of other
symptoms (16,17). However, given the low levels of
depression in our patient population (18), we did not
expect to identify this particular subgroup in our cluster
analysis.
PATIENTS AND METHODS
Study population. The study population was derived
from a subgroup of the Brigham and Women’s Hospital
Rheumatoid Arthritis Sequential Study (BRASS). The BRASS
involves a prospective observational cohort of 1,300 partici-
pants over the age of 18 years whose diagnosis of RA was
confirmed by a board-certified rheumatologist (19). Of these
participants, 208 participated in a substudy to examine the
effects of widespread pain on functional status. Exclusion
criteria for the current study included the following: 1) absence
of pain (average pain severity score of 0 on the Brief Pain
Inventory [BPI]), and 2) incomplete data for any of the
clustering variables. Written informed consent was obtained
from all participants for both the BRASS study and for the
substudy on widespread pain and functional status. This study
was approved by the Partners Institutional Review Board.
Measures. Inflammation. Board-certified rheumatolo-
gists performed 28-joint counts to assess tenderness and swell-
ing. Both the physicians and the patients also provided global
assessments of disease activity (on 0–100 numeric rating
scales). Samples of blood were collected for a standard labo-
ratory panel, including measurement of the CRP level. Based
on these measures, the Disease Activity Score in 28 joints using
the CRP level (DAS28-CRP) was calculated (20).
Pain. To quantify pain intensity, we used the average
pain severity score on the short form version of the BPI
(BPI-sf). The BPI-sf is a validated, 9-question survey that
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assesses the sensory and reactive aspects of clinical pain. The
sensory portion includes questions regarding the severity of
pain on average (the average BPI-sf pain severity score) as well
as the severity of pain “at its worst,” “at its least,” and “right
now” (21). We also measured the distribution of nonjoint pain
using the Widespread Pain Index (WPI), which assesses pain in
19 areas (22). The distribution of joint pain was quantified
using the joint score from the Rheumatoid Arthritis Disease
Activity Index (RADAI) (23,24).
Mood. Depression and anxiety were measured using
the Hospital Anxiety and Depression Scale (HADS), a 14-item
questionnaire validated in physically ill patients (25).
Fatigue. The fatigue numeric rating scale on the Mul-
tidimensional Health Assessment Questionnaire (MD-HAQ)
was used to assess fatigue. Specifically, the MD-HAQ presents
the question, “How much of a problem has fatigue or tiredness
been for you in the past week?” (26).
Illness burden. We quantified illness burden using a
count of patient-reported symptoms of headaches, migraines,
poor concentration, poor memory, and poor word-finding.
This measure was based on the concept of illness burden
described by Murphy et al in a similar cluster analysis of
symptoms in osteoarthritis patients (16).
Sleep problems. Sleep problems were measured using
the Medical Outcomes Study (MOS) Sleep Problems Index II,
a validated, 12-item questionnaire that assesses sleep problems
in chronically ill populations (27).
Catastrophizing. The Pain Catastrophizing Scale (PCS),
a validated 13-item scale that assesses negative emotional and
cognitive processes (e.g., helplessness, rumination, pessimism,
and magnification of symptoms), was used to evaluate cata-
strophizing (28).
Polysymptomatic features of chronic widespread pain.
Polysymptomatic features of chronic widespread pain (e.g.,
fatigue, somatic symptoms, cognitive and sleep problems,
decreased pain threshold, etc.), referred to by Wolfe as
“fibromyalgianess” (29), were measured by summing the WPI
and the Symptom Severity Score, a measure that also assesses
the presence of headaches, abdominal pain, and depression.
Both the WPI and the Symptom Severity Score are compo-
nents of the American College of Rheumatology 2010 diag-
nostic criteria for fibromyalgia (22).
Statistical analysis. Descriptive measures, including
median values, interquartile ranges (IQRs), and frequencies,
were determined. Based on Formann’s method (30), which
states that the maximum number of clustering variables should
be m, where sample size  2m, the number of clustering
variables was limited to 7 (31,32). Clustering variables were
chosen based on those reported in previous studies, in which
the presence of depression–pain–fatigue clusters and fatigue–
insomnia–pain clusters has been described in populations of
patients with chronic disease, such as cancer and osteoarthritis
(16). In addition, catastrophizing was included as a measure of
negative cognitive and emotional processes, in accordance with
a study examining psychological subgrouping of patients with
low back pain (33).
The swollen joint count was included as a measure of
joint inflammation. The swollen joint count was chosen to
represent RA-related inflammation because 1) the number of
swollen joints is considered to be an objective measure of
inflammation, whereas the tender joint count and physician’s
global assessment of disease activity may be influenced by
other factors, such as widespread pain sensitivity, and 2) the
number of swollen joints directly reflects the presence of active
inflammation at joint sites, whereas the CRP level is a marker
of overall systemic inflammation and the Sharp/van der Heijde
radiographic erosion score (34) reflects the extent of cumula-
tive damage, but not acute inflammation.
A hierarchical agglomerative clustering procedure with
Ward’s method, incorporating squared Euclidian distances,
was used to obtain the clusters. To determine the optimal
number of clusters, we used the cubic clustering criterion (35)
and constructed a dendrogram to visually inspect the distances
between clusters.
To determine the relative contribution of each cluster-
ing variable, all variables were included in a multivariate
analysis of variance (MANOVA) model with the cluster as-
signment as the independent variable. The clustering variables
were standardized by subtracting each data point from the
mean and dividing by the standard deviation. This standard-
ization process minimized deviations from normality, but some
variables, particularly the swollen joint count, illness burden,
and pain catastrophizing, continued to have a skewed distribu-
tion. In general, the F-test, which is the basis of the
MANOVA, is robust to non-normal distributions, particularly
when the sample size is large, because the sampling distribu-
tion of the mean value approximates the normal distribution
(central limit theorem) (36,37). We used the Wilks’  as an
evaluation of the dissimilarity measure between clusters. Un-
adjusted general linear regression models were used to identify
differences in clustering variables and in sociodemographic
and clinical characteristics across clusters.
A discriminant analysis was performed to examine
cluster groupings. To define the discriminant functions, a
constant value and 7 coefficients (one for each clustering
variable) were calculated for each cluster. To determine the
relative contribution of each clustering variable to the discrim-
inant functions, the total canonical structure was analyzed. The
proportion of misclassified observations in each group was
assessed. All statistical analyses were performed using the SAS
software package version 9.2 (SAS Institute).
RESULTS
Characteristics of the patients. Among the
1,300 RA patients in the BRASS, 208 completed
baseline questionnaires for the substudy examining the
effects of widespread pain on functional status. Of these
208 patients, 13 (6.3%) were excluded because they did
not report any pain, and 26 (12.5%) were excluded due
to incomplete data for at least one clustering variable.
The majority of missing data were from participants who
did not complete the PCS, the MD-HAQ fatigue scale,
or questions used to calculate illness burden. These 26
participants did not differ from those who had complete
data for any of the clustering variables assessed (swollen
joint count, BPI-sf average pain intensity, HADS de-
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pression score, MD-HAQ fatigue score, illness burden,
MOS Sleep Problems Index II score, or PCS score).
Of the 169 RA patients included in this analysis,
136 (80.5%) were female and 157 (94.6%) of 166 (3
patients did not provide information on race) were white
(Table 1). The median disease duration was 13.0 years
(IQR 7.0–23.0 years). Of 166 patients (3 were missing
data regarding rheumatoid factor status), 104 (62.7%)
were rheumatoid factor positive. The median DAS28-
CRP score was 2.6 (IQR 2.0–3.8), and the median
MD-HAQ fatigue score was 35 (IQR 15.0–65.0). The
median BPI-sf pain score was 3.0 (IQR 2.0–5.0).
Cluster analysis. The cluster analyses identified 3
subgroups of RA patients (Figure 1). Cluster 1 consisted
of the largest number of patients (n  89; 52.7%) and
was characterized by the lowest swollen joint counts
(median 0.0, IQR 0.0–1.0; each P 0.0001 versus cluster
2 or cluster 3) (Table 2). Patients in cluster 1 also had
the lowest levels of fatigue (each P  0.0001 versus
cluster 2 or cluster 3) and lowest levels of depression
(P  0.01 versus cluster 2 and P  0.004 versus cluster
3). Cluster 2 consisted of 57 patients (33.7%) and was
characterized by low swollen joint counts (median 2.0,
IQR 0.0–4.0) and high levels of fatigue, pain catastro-
phizing, and sleep problems. Cluster 3 consisted of 23
patients (13.6%) and was characterized by high swollen
joint counts and moderate levels of fatigue, pain cata-
strophizing, and sleep problems.
MANOVA confirmed that the clustering vari-
ables were significantly different between the 3 groups
(Wilks’   0.08, F[df 14, 320]  60.0, P  0.0001).
These differences were confirmed in unadjusted general
linear regression models, which showed statistically sig-
nificant differences in all clustering variables (P  0.03),
except for illness burden (P 0.06), between the groups.
Clinical variables among subgroups. Cluster 1.
Compared to clusters 2 and 3, patients in cluster 1 had
the lowest WPI scores (median 2 in cluster 1 versus
median 5 in clusters 2 and 3; P  0.0006 versus cluster 2
and P  0.005 versus cluster 3), consistent with the
localized distribution of pain in these patients. Measures
of inflammatory disease activity were also significantly
lower in cluster 1 than in clusters 2 and 3 (Table 3). The
median DAS28-CRP score was 2.4 in cluster 1, com-
pared to a median score of 2.9 in cluster 2 (P  0.0005)
and a median score of 5.1 in cluster 3 (P  0.0001), and
the median physician’s global assessment of disease
activity score was 10 in cluster 1, compared to a median
score of 20 in cluster 2 (P  0.02) and a median score of
40 in cluster 3 (P  0.0001). Similarly, the median
patient’s global assessment of disease activity score was
15 in cluster 1, compared to a median score of 30 in
clusters 2 and 3 (P  0.0001 versus cluster 2 and P 
0.001 versus cluster 3). Patients in cluster 1 also had low
CRP levels (median level 1.7 mg/liter), low Sharp/van
der Heijde radiographic erosion scores (median score 1),
and low Sharp/van der Heijde radiographic joint space
narrowing scores (median score 2), although these val-
ues were not significantly different from those in cluster
2.
Figure 1. Canonical discriminant functions used to differentiate clus-
ters of patients with established rheumatoid arthritis based on cluster-
ing analyses. Two discriminant functions significantly distinguished the
3 clusters, accounting for 88.3% and 11.7% of the variance (each P 
0.0001). Three potential outliers (designated in the orange square)
were noted.
Table 1. Clinical characteristics of the rheumatoid arthritis study
population (n  169)*
Age, median (IQR) years 58.0 (50.0–65.0)
Female, no. (%) 136 (80.5)
White, no. (%) 157 (94.6)†
BMI, median (IQR) kg/m2 26.1 (23.4–29.8)
Disease duration, median (IQR) years 13.0 (7.0–23.0)
Rheumatoid factor positive, no. (%) 104 (62.7)†
DAS28-CRP, median (IQR) 2.6 (2.0–3.8)
BPI-sf pain intensity score, median (IQR) 3.0 (2.0–5.0)
Fatigue score, median (IQR) 35.0 (15.0–65.0)
Current DMARD use, no. (%) 149 (88.2)
Current biologic DMARD use, no. (%) 98 (58.0)
Current synthetic DMARD use, no. (%) 108 (63.9)
* IQR interquartile range; BMI body mass index; DAS28-CRP
Disease Activity Score in 28 joints using the C-reactive protein level;
BPI-sf  short form version of the Brief Pain Inventory; DMARD 
disease-modifying antirheumatic drug.
† Percentages of patients are derived from a denominator of 166, due
to missing data.
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(n  23) P†
Sociodemographic
Age, years 58.0 (50.0–65.0) 56.0 (49.0–64.0) 60.0 (52.0–70.0) 0.23
Female, no. (%) 70 (78.7) 47 (82.5) 19 (82.6) 0.82
White, no. (%)‡ 84 (95.5) 51 (91.1) 22 (100) 0.25
BMI, kg/m2 26.2 (22.9–29.6) 25.7 (23.3–29.1) 28.3 (24.8–31.1) 0.14
Clinical
Disease duration, years 12.0 (7.0–21.0) 13.0 (8.0–22.0) 22.0 (13.0–27.0)§ 0.006
Rheumatoid factor positive, no. (%)¶ 51 (58.0) 34 (61.8) 19 (82.6) 0.09
DAS28-CRP 2.4 (1.7–3.0) 2.9 (2.2–3.8)# 5.1 (4.5–5.9)§ 0.0001
CRP, mg/liter 1.7 (0.6–2.9) 1.7 (0.6–4.8) 2.6 (1.5–22.2)§ 0.0003
Tender joint count (of 28 joints) 1.0 (0.0–3.0) 2.0 (0.0–6.0) 14.0 (12.0–16.0)§ 0.0001
Patient’s global assessment of disease
activity (scale 0–100)
15.0 (5.0–25.0) 30.0 (15.0–60.0)# 30.0 (20.0–50.0)# 0.0001
Physician’s global assessment of disease
activity (scale 0–100)
10.0 (10.0–30.0) 20.0 (10.0–30.0)# 40.0 (30.0–50.0)§ 0.0001
Sharp/van der Heijde erosion score (scale 0–160) 1.0 (0.0–10.0) 1.0 (0.0–4.0) 12.0 (1.0–31.0)§ 0.03
Sharp/van der Heijde joint space narrowing score
(scale 0–120)
2.0 (0.0–23.0) 2.0 (0.0–18.5) 26.0 (2.0–53.0)§ 0.002
RADAI joint count (scale 0–10) 1.0 (0.4–1.9) 1.7 (0.8–2.9)# 2.7 (1.0–3.3)# 0.0007
Widespread Pain Index (scale 0–19) 2.0 (1.0–5.0) 5.0 (2.0–7.0)# 5.0 (2.0–8.0)# 0.0004
Polysymptomatic features of chronic widespread
pain (scale 0–31)
7.0 (4.0–9.0) 10.0 (7.0–14.0)# 11.0 (6.0–15.0)# 0.0001
Medications, no. (%)
Current use
DMARDs 85 (95.5) 47 (82.5)# 17 (73.9)# 0.004
Biologic DMARDs 54 (60.7) 33 (57.9) 11 (47.8) 0.54
Synthetic DMARDs 64 (71.9) 32 (56.1)# 12 (52.2)# 0.07
Corticosteroids 14 (15.7) 8 (14.0) 5 (21.7) 0.69
Past use
DMARDs 89 (100) 57 (100) 23 (100) –
Biologic DMARDs 61 (68.5) 44 (77.2) 20 (87.0) 0.16
Synthetic DMARDs 89 (100) 57 (100) 23 (100) –
* Except where indicated otherwise, values are the median (interquartile range). BMI  body mass index; DAS28-
CRP  Disease Activity Score in 28 joints using the C-reactive protein level; RADAI Rheumatoid Arthritis Disease Activity
Index; DMARDs  disease-modifying antirheumatic drugs.
† P value for overall difference, signifying any one cluster is different from the others.
‡ Percentages of patients are derived from denominators of 88, 56, and 22 for clusters 1, 2, and 3, respectively, due to missing
data.
§ Significantly different from clusters 1 and 2 (P  0.05).
¶ Percentages of patients are derived from denominators of 88, 55, and 23 for clusters 1, 2, and 3, respectively, due to missing
data.
# Significantly different from cluster 1 (P  0.05).







(n  23) P†
Swollen joint count 0.0 (0.0–1.0) 2.0 (0.0–4.0)‡ 12.0 (10.0–14.0)‡§ 0.0001
BPI-sf pain intensity 3.0 (2.0–4.0) 3.0 (2.0–5.0)‡ 3.0 (2.0–5.0) 0.03
Fatigue 20.0 (10.0–30.0) 70.0 (50.0–80.0)‡ 60.0 (25.0–80.0)‡§ 0.0001
Sleep problems 27.2 (16.1–41.1) 38.3 (27.2–46.7)‡ 35.6 (17.5–47.8) 0.009
HADS depression 3.0 (1.0–5.0) 4.0 (1.0–7.0)‡ 5.0 (2.0–8.0)‡§ 0.004
Illness burden 1.0 (0.0–3.0) 2.0 (1.0–3.0)‡ 1.0 (0.0–2.0)§ 0.06
Pain catastrophizing 6.0 (1.0–12.0) 12.0 (5.0–21.0)‡ 9.0 (3.0–18.0) 0.0001
* Values are the median (interquartile range). BPI-sf  short form version of the Brief Pain Inventory;
HADS  Hospital Anxiety and Depression Scale.
† P value for overall difference, signifying any one cluster is different from the others.
‡ Significantly different from cluster 1 (P  0.05).
§ Significantly different from cluster 2 (P  0.05).
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Cluster 2. Similar to cluster 1, patients in cluster 2
had low CRP levels (median 1.7 mg/liter), low tender
joint counts (median 2), low Sharp/van der Heijde
radiographic erosion scores (median 1), and low Sharp/
van der Heijde radiographic joint space narrowing
scores (median 2). However, patients in cluster 2 had
significantly higher DAS28-CRP scores than did patients
in cluster 1 (P  0.0005), likely because the patient’s
global assessment of disease activity scores were higher
in cluster 2 (P  0.0001). Patients in cluster 2 also had
significantly higher physician’s global assessment of dis-
ease activity scores (P  0.02) and more widespread
distribution of pain, as assessed by the WPI score (P 
0.0006), as compared to cluster 1.
Cluster 3. Compared to clusters 1 and 2, patients
in cluster 3 had significantly higher levels of inflamma-
tory disease activity, as assessed by the DAS28-CRP
score (P  0.0001), the CRP level (P  0.0001), the
tender joint count (P  0.0001), and the physician’s
global assessment of disease activity (P  0.0001).
Although the patient’s global assessment of disease
activity scores were significantly higher in cluster 3
compared to cluster 1 (P  0.001), the patient’s global
assessment of disease activity scores were not higher in
cluster 3 compared to cluster 2. Measures of joint
destruction were consistently higher in cluster 3 com-
pared to clusters 1 and 2 (P 0.009 for erosions and P
0.0005 for joint space narrowing). Moreover, patients in
cluster 3 had a significantly longer disease duration (P
0.002) and significantly more patients in cluster 3 were
currently taking disease-modifying antirheumatic drugs
(DMARDs) (P  0.04) when compared to patients in
clusters 1 and 2. Past DMARD use did not differ across
the groups.
Discriminant functions. The clusters were distin-
guished by 2 discriminant functions, corresponding to
88.3% and 11.7% of the variance (each P 0.0001). The
coefficients for the discriminant functions for each clus-
ter are reported in Table 4. Function 1 was mostly
influenced by the swollen joint count and fatigue,
whereas function 2 was mostly influenced by fatigue and
pain catastrophizing. Function 1 was primarily responsi-
ble for distinguishing clusters 1 and 2 from cluster 3,
whereas function 2 was required to distinguish between
clusters 1 and 2. Using discriminant function analysis, we
were able to correctly categorize 95.9% of the partici-
pants into the groups determined by cluster analysis.
Outliers. Three potential outliers were noted.
Each was grouped into cluster 1, although, based on
graphic presentation, the characteristics of these 3 pa-
tients who were outliers appeared more similar to those
of patients in cluster 2 (Figure 1). These individuals had
no swollen joints but had high levels of pain catastroph-
izing, sleep problems, and fatigue. Using discriminant
analyses, 2 of these 3 patients were ultimately re-
categorized into cluster 2.
DISCUSSION
The theory underlying this study is that symptoms
such as pain, fatigue, and sleep problems may be pre-
dominantly associated with either 1) active inflamma-
tory disease or 2) a chronic, noninflammatory pain
syndrome. Our results characterized 3 distinct subgroups
of RA patients on the basis of inflammatory disease
activity (swollen joints), co-occurring symptoms (e.g.,
pain, fatigue, sleep problems), cognitive and emotional
factors (e.g., catastrophizing and depression), and func-
tional illness burden. Although the majority of the RA
patients in this cohort were doing well (cluster 1), a
significant number continued to have multiple areas of
pain and difficulties with fatigue, sleep, and catastroph-
izing. Of the 80 patients who had significant problems in
these areas, 23 (28.8%) had active inflammatory disease,
manifested by elevated swollen joint counts, elevated
tender joint counts, and increased serum levels of CRP
(cluster 3). In contrast, the remaining 71.2% (cluster 2;
n  57) had low levels of inflammatory disease activity,
despite having the worst patient’s global assessment of
disease activity scores and the highest levels of fatigue
and pain catastrophizing of all 3 groups. These patients
also had low Sharp/van der Heijde radiographic erosion
and joint space narrowing scores, indicating that joint
damage was not a major cause of the pain and mood
disturbances. Taken together, these results suggest that
cluster 2 represents a subgroup of RA patients who
likely have a more centralized chronic widespread pain
syndrome, such as fibromyalgia, in addition to RA.
Table 4. Discriminative analysis of cluster characteristics*
Variable Cluster 1 Cluster 2 Cluster 3
Constant 2.31 1.95 18.8
Swollen joint count 3.74† 0.09 14.26†
BPI-sf pain intensity 0.59 0.47 1.11
Fatigue 2.57† 2.35† 4.13†
Sleep problems 1.18 0.92† 2.28
HADS depression 0.12 0.12 0.16
Illness burden 0.03 0.14 0.24
Pain catastrophizing 0.69 0.62 1.14
* Values are the coefficients for discriminant functions for each
cluster. BPI-sf  short form version of the Brief Pain Inventory;
HADS  Hospital Anxiety and Depression Scale.
† Highest variable loads for each cluster.
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Several other studies have used cluster analysis to
identify subgroups of RA patients, but, within each
study, the clustering variables were limited to one di-
mension (e.g., pain behaviors or psychosocial measures)
(38,39). To our knowledge, none of those prior studies
have included a wide assessment of clinical factors, such
as inflammatory disease activity, cognitive and emo-
tional factors, and functional illness burden, as we did in
our study. The study most similar to ours was a cluster
analysis of 104 RA patients that was based on observed
pain behaviors (guarding, bracing, active rubbing, gri-
macing, sighing, and rigidity) (38). That study yielded 5
subgroups with varying behavior patterns, ranging from
those with very few pain behaviors to those with multiple
distressing behaviors. Although the subgroups differed
in behavior patterns, all 5 subgroups of patients reported
having a similar intensity of pain, highlighting that there
may be a disconnect between physical responses to pain
and verbal reports of pain.
In a large longitudinal study, cluster analysis was
used to classify 561 RA patients based on 5 psychosocial
measures (ability to cope, RA impact, health satisfac-
tion, adequacy of social support, psychological mastery)
(39). Those authors identified 3 subgroups of psychoso-
cial risk, which were predictive of the development of
depression, poor functional status, and global pain over
an 8-year period. These results showcase the ability of
cluster analysis to identify clinically meaningful sub-
groups. Notably, no previous studies have used cluster
analysis to identify subgroups with similar sources and
patterns of pain in an inflammatory arthritis population,
such as RA.
However, in populations of patients with chronic,
noninflammatory pain, researchers have frequently
identified subgroups of patients with widespread pain
and psychosocial impairment in the absence of inflam-
mation and the absence of other obvious causes of pain.
A cluster analysis of 104 older women identified 3
distinct groups, which were strikingly similar to the
clusters defined in this study: 1) a “healthy” group, 2) a
group with high levels of psychosocial distress and illness
burden, and 3) a group with poor physical health and
moderate levels of psychosocial distress (40). Similarly,
in a cohort of 121 patients with chronic neck pain, 3
distinct subgroups were noted, which varied in the
severity of psychosocial distress, sleep disorder, and
disability (41). In a longitudinal study of 843 pediatric
patients with functional abdominal pain, Walker and
colleagues used a variety of clustering variables, includ-
ing pain intensity, gastrointestinal symptoms, coping
abilities, catastrophizing, negative affection, and physical
activity, to categorize patients into 3 subgroups, includ-
ing a “high pain dysfunctional” group of patients in
whom there was an associated high risk of functional
abdominal pain disorder in adolescence/adulthood (42).
Compared to the cluster analyses done in pa-
tients with noninflammatory chronic pain conditions,
our results are most similar to those in a study that used
cluster analysis to characterize patients with symptom-
atic osteoarthritis of the knee or hip (16). Both our
current study and that prior study identified a group of
patients with high levels of pain, fatigue, sleep problems,
and mood disturbances, comprising approximately one-
third of the study population. In the osteoarthritis study,
the chronic widespread pain group also had significantly
higher levels of illness burden, assessed by MANOVA.
In our study, illness burden was not significantly differ-
ent between the groups based on MANOVA (P 0.06).
The lack of a difference may partially be attributed to
our measure of illness burden, which was assessed based
on 5 common somatic symptoms, as opposed to the 41
symptoms used in the previous study. Thus, we may not
have captured the full spectrum of illness burden. We do
note, however, that when the clusters were separately
compared with each other using a general linear model,
the differences in illness burden between cluster 2 and
clusters 1 and 3 were both statistically significant at P 
0.04 (Table 2).
Post hoc analyses highlighted key differences
between pain measures. Although the BPI-sf average
pain severity scores did not differ between groups,
clinical pain measures that incorporated the distribution
of pain (e.g., the RADAI joint count and the WPI)
significantly distinguished cluster 1 from clusters 2 and 3,
with patients in cluster 1 having RADAI and WPI scores
that were significantly lower than those in patients in the
other 2 clusters. However, neither the RADAI joint
count nor the WPI significantly differentiated cluster 2
from cluster 3, even though the RADAI and WPI are
designed to focus on joint pain and nonjoint pain,
respectively. Interestingly, the tender joint count was
significantly lower among patients in cluster 2 compared
to patients in cluster 3, suggesting that, despite previous
reports of flaws in its specificity for assessing arthritis
pain (43), the tender joint count may offer greater
discriminating capacity compared to either the RADAI
or the WPI.
The results of this study have important theoret-
ical and clinical implications. Specifically, our results
indicate that, in a population of patients with established
RA, many continue to have widespread pain, despite
relatively low levels of inflammation. Thus, physicians
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should carefully assess symptoms such as fatigue, sleep
problems, depression, and pain catastrophizing when
evaluating RA patients, particularly if these patients
provide high scores of disease activity in the face of low
scores for objective measures of inflammation. In the-
ory, this group may be more likely to respond to
psychological interventions (e.g., cognitive behavioral
therapy, pain-coping skills training) (44) or to medica-
tions aimed at treating chronic widespread pain syn-
dromes, such as serotonin norepinephrine reuptake in-
hibitors and neuroleptic pain medications. Studies are
currently underway to examine whether similar medica-
tions may be effective for RA patients with stable
inflammatory disease activity who continue to have
widespread pain and fatigue.
This study does have limitations. Specifically, the
generalizability of these findings is limited by the study
population, a cohort of patients with established RA
(median disease duration 13 years) treated at a single
academic medical institution. Among this population,
88% of patients were treated with a DMARD, including
58.0% who were taking biologic DMARDs. The propor-
tion of patients with active inflammatory disease would
likely be much higher in a population of patients who are
not as intensively treated. Although patients in cluster 3
were significantly less likely than patients in clusters 1
and 2 to be taking a DMARD at the time of the study,
all of the patients had been treated with DMARDs in
the past. Past biologic DMARD use was not significantly
different between the clusters, with 87% of the patients
in cluster 3 reporting past use of biologic DMARDs.
These results suggest that cluster 3 may consist of
patients whose disease was particularly resistant to
treatment.
Other limitations include the use of a hierarchical
agglomerative clustering technique, which may be influ-
enced by outliers, and the lack of quantitative informa-
tion about pain mechanisms. Future studies are needed
to replicate these findings and to further characterize
these patients using quantitative sensory testing tech-
niques. Quantitative sensory testing may help determine
whether patients in cluster 2 have measurable differ-
ences in central pain regulatory mechanisms, such as loss
of conditioned pain modulation, which are associated
with chronic widespread pain conditions. The identifica-
tion of different subgroups of RA patients may lead to a
better understanding of the mechanisms causing pain
and fatigue in RA, which can facilitate the identification
of appropriate treatment targets.
In conclusion, a clustering algorithm based on the
swollen joint count, co-occurring symptoms (e.g., pain,
fatigue, sleep problems), psychological distress (pain
catastrophizing and depression), and functional illness
burden identified 3 groups of patients with established
RA. Although most patients were doing well, 47.3%
continued to have moderate to high levels of pain,
fatigue, and sleep problems. The majority of these
patients had low markers of inflammation but high levels
of catastrophizing, consistent with the characteristics of
a chronic widespread pain syndrome. These results are
poignant because they indicate that 1) chronic wide-
spread pain syndromes are common among patients with
established RA, 2) active inflammatory disease may
account for problems with pain, fatigue, and mood
disturbance in only a minority of patients, and 3) chronic
widespread pain syndromes are associated with signifi-
cantly diminished quality of life, even compared to that
in patients with active inflammatory disease.
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